Clinical effect of Shengyang Jianpi Tiaogan decoction in treatment of diarrhea-predominant irritable bowel syndrome with liver depression and spleen deficiency:An analysis of 40 cases
Objective:To investigate the clinical effect of Shengyang Jianpi Tiaogan decoction in the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D)with liver depression and spleen deficiency.Methods:A total of 80 IBS-D patients with liver depression and spleen deficiency were divided into treatment group and control group using a random number table,with 40 patients in each group.The patients in the treatment group received Shengyang Jianpi Tiaogan decoction,while those in the control group received trimebutine maleate tablets and Bifid-triple viable capsules,and the course of treatment was 4 weeks for both groups.The two groups were compared in terms of the change in tradition-al Chinese medicine(TCM)syndrome score after treatment,the treatment outcome of TCM syndrome was assessed,and adverse events were recorded.Results:The treatment group had a significantly higher overall response rate of TCM syn-drome than the control group after treatment[92.50％(37/40)vs 77.50％(31/40),P＜0.05],and follow-up on day 28 after drug withdrawal showed that the treatment group still had a significantly higher overall response rate of TCM syn-drome than the control group[85.00％(34/40)vs 67.50％(27/40),P＜0.01].Both groups had a significant change in total TCM syndrome score on days 14 and 28 of treatment,and there was a significant difference between the two groups(P＜0.01),with little adverse effect in either group.Conclusion:Shengyang Jianpi Tiaogan decoction has a better clinical effect than the Western medicine drugs trimebutine maleate tablets and Bifid-triple viable capsules in the treatment of IBS-D with liver depression and spleen deficiency,with a favorable safety profile.
NETL
NSTL
万方数据
